Literature DB >> 25375838

Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.

Mark E Flanagan1, Joseph A Abramite, Dennis P Anderson, Ann Aulabaugh, Upendra P Dahal, Adam M Gilbert, Chao Li, Justin Montgomery, Stacey R Oppenheimer, Tim Ryder, Brandon P Schuff, Daniel P Uccello, Gregory S Walker, Yan Wu, Matthew F Brown, Jinshan M Chen, Matthew M Hayward, Mark C Noe, R Scott Obach, Laurence Philippe, Veerabahu Shanmugasundaram, Michael J Shapiro, Jeremy Starr, Justin Stroh, Ye Che.   

Abstract

Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymatic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein. However, covalent approaches carry additional risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets. Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biologically relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles. We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25375838     DOI: 10.1021/jm501412a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  59 in total

1.  Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach.

Authors:  Rukmankesh Mehra; Reena Chib; Gurunadham Munagala; Kushalava Reddy Yempalla; Inshad Ali Khan; Parvinder Pal Singh; Farrah Gul Khan; Amit Nargotra
Journal:  Mol Divers       Date:  2015-08-01       Impact factor: 2.943

Review 2.  Covalent targeting of acquired cysteines in cancer.

Authors:  Marieke Visscher; Michelle R Arkin; Tobias B Dansen
Journal:  Curr Opin Chem Biol       Date:  2015-11-28       Impact factor: 8.822

3.  Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines.

Authors:  Mami Sato; Hirokazu Fuchida; Naoya Shindo; Keiko Kuwata; Keisuke Tokunaga; Guo Xiao-Lin; Ryo Inamori; Keitaro Hosokawa; Kosuke Watari; Tomohiro Shibata; Naoya Matsunaga; Satoru Koyanagi; Shigehiro Ohdo; Mayumi Ono; Akio Ojida
Journal:  ACS Med Chem Lett       Date:  2020-04-08       Impact factor: 4.345

4.  Covalent Tethering of Fragments For Covalent Probe Discovery.

Authors:  Stefan G Kathman; Alexander V Statsyuk
Journal:  Medchemcomm       Date:  2016-01-28       Impact factor: 3.597

5.  Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Authors:  Chuhui Huang; Si Si Liew; Grace R Lin; Anders Poulsen; Melgious J Y Ang; Brian C S Chia; Sin Yin Chew; Zekui P Kwek; John L K Wee; Esther H Ong; Priya Retna; Nithya Baburajendran; Rong Li; Weixuan Yu; Xiaoying Koh-Stenta; Anna Ngo; Sravanthy Manesh; Justina Fulwood; Zhiyuan Ke; Hwa Hwa Chung; Sugunavathi Sepramaniam; Xin Hui Chew; Nurul Dinie; May Ann Lee; Yun Shan Chew; Choon Bing Low; Vishal Pendharkar; Vithya Manoharan; Susmitha Vuddagiri; Kanda Sangthongpitag; Joma Joy; Alex Matter; Jeffrey Hill; Thomas H Keller; Klement Foo
Journal:  ACS Med Chem Lett       Date:  2019-05-23       Impact factor: 4.345

6.  Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.

Authors:  Yudao Shen; Fengling Li; Magdalena M Szewczyk; Levon Halabelian; Kwang-Su Park; Irene Chau; Aiping Dong; Hong Zeng; He Chen; Fanye Meng; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Peter J Brown; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2020-05-14       Impact factor: 7.446

7.  Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.

Authors:  Youngsook Shin; Joon Won Jeong; Ryan P Wurz; Pragathi Achanta; Tara Arvedson; Michael D Bartberger; Iain D G Campuzano; Ray Fucini; Stig K Hansen; John Ingersoll; Jeffrey S Iwig; J Russell Lipford; Vu Ma; David J Kopecky; John McCarter; Tisha San Miguel; Christopher Mohr; Sudi Sabet; Anne Y Saiki; Andrew Sawayama; Steven Sethofer; Christopher M Tegley; Laurie P Volak; Kevin Yang; Brian A Lanman; Daniel A Erlanson; Victor J Cee
Journal:  ACS Med Chem Lett       Date:  2019-08-20       Impact factor: 4.345

8.  Targeted Covalent Inhibition of Telomerase.

Authors:  Rick C Betori; Yue Liu; Rama K Mishra; Scott B Cohen; Stephen J Kron; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2020-02-24       Impact factor: 5.100

Review 9.  Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery.

Authors:  Kenneth K Hallenbeck; David M Turner; Adam R Renslo; Michelle R Arkin
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

10.  Development of Selective Covalent Janus Kinase 3 Inhibitors.

Authors:  Li Tan; Koshi Akahane; Randall McNally; Kathleen M S E Reyskens; Scott B Ficarro; Suhu Liu; Grit S Herter-Sprie; Shohei Koyama; Michael J Pattison; Katherine Labella; Liv Johannessen; Esra A Akbay; Kwok-Kin Wong; David A Frank; Jarrod A Marto; Thomas A Look; J Simon C Arthur; Michael J Eck; Nathanael S Gray
Journal:  J Med Chem       Date:  2015-08-18       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.